Ascendis Pharma launches Yorvipath, first FDA-approved treatment for adult hypoparathyroidism in the U.S

Ascendis Pharma A/S announced the U.S. launch of Yorvipath (palopegteriparatide), a once-daily prodrug of parathyroid hormone (PTH), according to a company press release. Designed to provide continuous PTH exposure over a 24-hour period, it is the first FDA-approved treatment for adult hypoparathyroidism.

Patty Keating, Executive Director of the HypoPARAthyroidism Association, highlighted the positive impact observed during clinical trials and expressed enthusiasm for the treatment’s availability. Jan Mikkelsen, CEO of Ascendis Pharma, emphasized the company’s commitment to addressing the unmet needs of the hypoparathyroidism community and ensuring broad, affordable access to Yorvipath.

To support patients and healthcare providers, Ascendis has introduced the Yorvipath team within its U.S. Ascendis Signature Access Program. This initiative provides resources such as clinical education, insurance assistance, injection training, and financial support for eligible patients.

Read the full press release here.